Login to Your Account

Other News To Note

Monday, March 14, 2011
Shares in Cell Therapeutics Inc., of Seattle, (NASDAQ:CTIC) gained 40.2 percent Friday on news a day earlier that the company had a final pivotal trial design for pixantrone in diffuse large B-cell lymphoma, following discussions with the FDA. The stock gained 9 cents to close at 30 cents. The study, designated PIX 306, will compare a combination of pixantrone plus Rituxan (rituximab, Genentech Inc./Roche AG and Biogen Idec Inc.) to a combination of gemcitabine plus rituximab in patients with relapsed or refractory disease who have received one to three prior lines of therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription